Myriad Genetics, Inc.
Myriad Genetics, Inc., a leading player in the precision medicine industry, is headquartered in the United States. Founded in 1991, the company has established itself as a pioneer in genetic testing and molecular diagnostics, focusing on areas such as oncology, women's health, and hereditary cancer.
With a commitment to advancing healthcare through innovative solutions, Myriad offers a range of unique products and services, including genetic tests that provide critical insights for personalised treatment plans. The company has achieved significant milestones, including the development of the first FDA-approved genetic test for breast cancer risk assessment.
Recognised for its contributions to the field, Myriad Genetics holds a strong market position, continually striving to enhance patient outcomes through cutting-edge technology and research.
-15 vs industry average
Myriad Genetics, Inc.’s score of 23 is lower than 46% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Myriad Genetics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Myriad Genetics, Inc.'s reported carbon emissions
In 2022, Myriad Genetics, Inc. reported total greenhouse gas emissions of approximately 2,954,000 kg CO2e, comprising 1,414,000 kg CO2e from Scope 1 and 1,540,000 kg CO2e from Scope 2 emissions. Notably, the company has not disclosed any Scope 3 emissions data. Myriad Genetics has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and Scope 2 greenhouse gas emissions by 63% by 2035, using 2024 as the base year. Additionally, the company targets a 66.33% reduction in Scope 3 emissions related to purchased goods and services, as well as fuel- and energy-related activities, per USD value added within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support efforts to limit global warming to 1.5°C. Overall, Myriad Genetics is actively working towards significant emissions reductions, demonstrating a commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Myriad Genetics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Myriad Genetics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Myriad Genetics, Inc.
Frequently asked questions
Common questions about Myriad Genetics, Inc.’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project